Efficacy and Safety of ‘Prostane’ in the Management of Symptomatic Benign Prostatic Hyperplasia: A Clinical Evaluation

The objective of this study was to evaluate the efficacy and safety of Prostane, a herbal formulation, in alleviating the symptoms of Benign Prostatic Hyperplasia. Patients with benign prostatic hyperplasia were randomly given Prostane at a dose of 2 tablets, twice daily for 4 months. Subjective efficacy parameters were improvement in the symptoms and total American Urological Association symptom score. Objective efficacy parameters included uroflowmetric studies and an abdominal ultrasound, showing the approximate weight of the prostate and prostate specific antigen. The results showed that there was a statistically significant improvement in all efficacy parameters after treatment with Prostane. The symptoms showed that after 4 months of Prostane therapy, 84% of the patients showed improvement in hesitancy, 66% in intermittent flow, 74% in straining during urination, 70% had improvement in poor flow and 72% had a sense of complete micturition. The frequency of urination at night was less than 2 times in 68% of the patients. There was a reduction of 2 gm of prostatic weight and the maximum flow rate increased by 16.3% after treatment. The postvoid residual urine was less by 10.5 ml after 4 months of therapy. There was also improvement in the quality of life of all the patients. Thus, it can be concluded that Prostane was effective, safe, and well tolerated in the target benign prostatic hyperplasia population.